Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet 2016 被引用: 939